Monocytes and CAR‑T Cell Response in Multiple Myeloma
Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
This project will test whether the number and type of monocytes before and after CAR‑T cell therapy help predict how well CAR‑T works for adults with multiple myeloma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | CART |
| Locations | 1 site (Amiens) |
| Trial ID | NCT07180992 on ClinicalTrials.gov |
What this trial studies
This observational study will collect blood samples from adults with multiple myeloma who are scheduled to receive CAR‑T cell therapy at CHRU Amiens to measure monocyte counts and surface phenotypes. Samples will be obtained before CAR‑T infusion and at one or more time points afterward, and analyzed using quantitative assays and flow cytometry. Monocyte measures will be correlated with clinical response, relapse timing, and other outcome data to identify patterns linked to better or worse CAR‑T performance. The aim is to identify monocyte-related biomarkers in the tumor microenvironment that relate to CAR‑T durability and relapse risk.
Who should consider this trial
Good fit: Adults (18 or older) with multiple myeloma who are scheduled to receive CAR‑T therapy at CHRU Amiens, are affiliated with the social security system, and consent to participate are eligible.
Not a fit: Patients who are under 18, not receiving CAR‑T therapy, treated outside CHRU Amiens, or unable/unwilling to provide consent or adequate samples are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, findings could help predict which patients are more likely to have a durable response to CAR‑T and guide strategies to improve outcomes.
How similar studies have performed: Previous research has linked monocyte and macrophage activity in the marrow microenvironment to myeloma progression and CAR‑T outcomes, but using monocyte phenotyping as a reliable clinical predictor remains preliminary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years old * Treated for a multiple myeloma * CART cells treatment proposed * Affiliated to social security system * Agreed to participate to the study
Where this trial is running
Amiens
- CHRU Amiens — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Lydia Montes, MD
- Email: Montes.lydia@chu-amiens.fr
- Phone: 33+322088371
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.